Climb Bio, Inc.

CLYM

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Driehaus Capital RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management33.0%Dec 15, 2025

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 600,946Value: $2.4M

# Signal Note: Driehaus Capital Initiates CLYM Position Growth-focused Driehaus established a $2.4M stake in Climb Bio, a pre-clinical stage biotech focused on epigenetic therapies for cancer and neurological diseases. The entry suggests conviction in Climb's platform technology ahead of anticipated IND-enabling studies and regulatory catalysts, though the company remains early-stage with limited clinical validation and near-term value inflection points unclear.

RA Capital ManagementNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN2 funds SION2 funds NUVL2 funds PEPG2 funds RNA2 funds INSP2 funds JBIO2 funds ASND

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RA Capital initiates $77.7M position in Climb Bio (CLYM) RA Capital's new $77.7M stake in Climb Bio signals confidence in the company's lead program, CBL0137, a curaxin in development for liposarcoma and other solid tumors—a rare but addressable market with limited treatment options. The timing aligns with anticipated clinical data readouts expected in 2024-2025 that could validate the mechanism in this difficult-to-treat indication. This represents typical conviction-level sizing for RA Capital in early-to-mid stage oncology assets with differentiated mechanisms.